Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bemdaneprocel in advanced Parkinson's disease
NCT04802733Phase 1Completed
- Sponsor
- BlueRock Therapeutics
- Start
- May 2021
- Primary completion
- May 2023
- Modality
- Patient-derived iPSCs, Allogeneic iPSCs
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of bemdaneprocel in Parkinson's disease (PD), sponsored by BlueRock Therapeutics. Primary endpoint: Safety and Tolerability at 1 year. Started May 2021; status: completed.
02
Drugs
bemdaneprocel
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04802733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04802733.